Akers Scott R, Werner Thomas J, Rubello Domenico, Alavi Abass, Cheng Gang
aDepartment of Radiology, Philadelphia VA Medical Center bDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA cDepartment of Nuclear Medicine, PET/CT Centre, Radiology, Interventional Radiology NeuroRadiology, Medical Physics, Clinical Laboratory, Biomarkers Laboratory, Pathology, Microbiology, 'Santa Maria della Misericordia' Hospital, Rovigo, Italy.
Nucl Med Commun. 2016 Aug;37(8):825-32. doi: 10.1097/MNM.0000000000000513.
The aim of this study is to evaluate whether compromised renal function has an effect on the uptake and clearance of 2-deoxy-2-[F]fluoro-D-glucose (F-FDG) in normal tissues on F-FDG PET/CT imaging.
Patients were divided into three groups on the basis of their renal function status: 25 patients with normal renal function [estimated glomerular filtration rate (eGFR)>90 ml/min], 21 patients with mildly compromised renal function (90≥eGFR≥60 ml/min), and 12 patients with moderate or severe compromised renal function (eGFR<60 ml/min). All patients underwent F-FDG PET/CT imaging at 1, 2, and 3 h after tracer injection. Maximum standardized uptake values (SUVmax) were obtained in regions of interest for multiple tissue types.
Serial SUV values from 1 to 3 h were measured for different tissues including the aortic blood pool, liver, spleen, lung, lymph nodes, and skeletal muscles. The SUV values of F-FDG uptake showed significantly decreased activity from 1 to 2 h as well as from 2 to 3 h for each tissue type, irrespective of renal function. There was no significant difference in SUVmean values between patients with normal and compromised renal functions, which was consistently observed for each tissue type and at each time point. In fact, the variance in individual SUV values within a group was more than the variance of SUV means between the groups with different renal functions for all tissue types and at 1-, 2-, or 3-h time points. Finally, the lack of dependence of SUV values in normal tissues on renal function is shown by very low r values when comparing SUV and eGFR.
Our data suggest that compromised renal function does not significantly compromise clearance of background activity of F-FDG PET imaging. As a result, adjustment of F-FDG dose or imaging time is not necessary in renal-impaired patients to achieve optimal imaging.
本研究旨在评估肾功能受损是否会对正常组织在氟代脱氧葡萄糖(F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)成像中对F-FDG的摄取和清除产生影响。
根据肾功能状况将患者分为三组:25例肾功能正常的患者[估计肾小球滤过率(eGFR)>90 ml/min],21例轻度肾功能受损的患者(90≥eGFR≥60 ml/min),以及12例中度或重度肾功能受损的患者(eGFR<60 ml/min)。所有患者在注射示踪剂后1、2和3小时接受F-FDG PET/CT成像。在多种组织类型的感兴趣区域获取最大标准化摄取值(SUVmax)。
测量了1至3小时不同组织(包括主动脉血池、肝脏、脾脏、肺、淋巴结和骨骼肌)的系列SUV值。无论肾功能如何,每种组织类型的F-FDG摄取SUV值在1至2小时以及2至3小时均显示出明显降低的活性。肾功能正常和受损患者之间的SUVmean值无显著差异,在每种组织类型和每个时间点均一致观察到这一点。实际上,对于所有组织类型以及在1、2或3小时时间点,组内个体SUV值的方差大于不同肾功能组之间SUV均值的方差。最后,当比较SUV和eGFR时,极低的r值表明正常组织中SUV值对肾功能缺乏依赖性。
我们的数据表明,肾功能受损不会显著影响F-FDG PET成像背景活性的清除。因此,肾功能受损患者无需调整F-FDG剂量或成像时间即可实现最佳成像。